Updated results of a phase I/II study of inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-hyper-CVD) as frontline therapy for older patients with acute lymphoblastic leukemia.

被引：1
|
作者：
Short, Nicholas James
Kantarjian, Hagop M.
O'Brien, Susan Mary
Ravandi, Farhad
Thomas, Deborah A.
Garcia-Manero, Guillermo
Daver, Naval Guastad
Borthakur, Gautam
Jain, Nitin
Konopleva, Marina
Sasaki, Koji
Pemmaraju, Naveen
Alvarado, Yesid
Jacob, Jovitta
Garris, Rebecca
Thompson, Philip A.
Cortes, Jorge E.
Jabbour, Elias
机构：
[1] Univ Texas MD Anderson Canc Ctr, Div Canc Med, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[3] Univ Calif Irvine, Irvine, CA USA
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.7014
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7014
引用
收藏
页数：5
相关论文
共 50 条
  • [31] CD22 Expression Level As a Predictor of Survival in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study
    Rafei, Hind
    Kantarjian, Hagop M.
    Sasaki, Koji
    Short, Nicholas J.
    Ravandi, Farhad
    Huang, Xuelin
    Khoury, Joseph D.
    Wang, Sa A.
    Jorgensen, Jeffrey L.
    Khouri, Issa F.
    Kebriaei, Partow
    Jain, Nitin
    Dabaja, Bouthaina S.
    Masarova, Lucia
    Kadia, Tapan M.
    Paul, Shilpa
    Nichols, Dan
    Garcia-Manero, Guillermo
    Burger, Jan A.
    DiNardo, Courtney D.
    Daver, Naval
    Montalban-Bravo, Guillermo
    Yilmaz, Musa
    Bose, Prithviraj
    Khouri, Rita
    Thompson, Philip A.
    Jacob, Jovitta
    Rostykus, Meagan
    Garris, Rebecca
    Konopleva, Marina
    O'Brien, Susan M.
    Jabbour, Elias
    BLOOD, 2020, 136
  • [32] Roleof Allogeneic Stem Cell Transplant (ASCT) in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina): Results from a Phase 2 Study
    Rafei, Hind
    Kantarjian, Hagop M.
    Sasaki, Koji
    Short, Nicholas J.
    Ravandi, Farhad
    Huang, Xuelin
    Khoury, Joseph D.
    Wang, Sa A.
    Jorgensen, Jeffrey L.
    Khouri, Issa F.
    Kebriaei, Partow
    Champlin, Richard E.
    Jain, Nitin
    Dabaja, Bouthaina S.
    Issa, Ghayas C.
    Pemmaraju, Naveen
    Kadia, Tapan M.
    Paul, Shilpa
    Jammal, Nadya
    Garcia-Manero, Guillermo
    Wierda, William G.
    DiNardo, Courtney D.
    Daver, Naval
    Montalban-Bravo, Guillermo
    Khouri, Rita
    Nasnas, Patrice
    Thompson, Philip A.
    Jacob, Jovitta
    Rostykus, Meagan
    Garris, Rebecca
    Konopleva, Marina
    O'Brien, Susan M.
    Jabbour, Elias
    BLOOD, 2020, 136
  • [33] Improved Outcomes with Low-Dose Inotuzumab and Mini-Hyper-CVD Followed By Blinatumomab Consolidation in Relapsed-Refractory Acute Lymphoblastic Leukemia: Results of a Phase II Study
    Haddad, Fadi
    Jabbour, Elias
    Short, Nicholas
    Jain, Nitin
    Huante, Emmanuel Almanza
    Sasaki, Koji
    Nasnas, Patrice
    Ravandi, Farhad
    Kebriaei, Partow
    Huang, Xuelin
    Konopleva, Marina
    Garcia-Manero, Guillermo
    Champlin, Richard E.
    Kadia, Tapan M.
    Takahashi, Koichi
    Daver, Naval
    Khoury, Joseph D.
    Jorgensen, Jeffrey L.
    Wang, Sa A.
    Jacob, Jovitta
    Garris, Rebecca
    Kantarjian, Hagop
    BLOOD, 2022, 140 : 11698 - 11701
  • [34] Phase 2 Trial of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Patients with Newly Diagnosed Philadelphia ChromosomeNegative B-Cell Acute Lymphoblastic Leukemia
    Jen, lWei-Ying
    Jabbour, Elias
    Haddad, Fadi G.
    Short, Nicholas J.
    Jain, Nitin
    Kadia, Tapan M.
    Daver, Naval
    Borthakur, Gautam
    Nasr, Lewis
    DiNardo, Courtney D.
    Zoghbi, Marianne
    Jacob, Jovitta
    Roy, Edith
    Loiselle, Christopher
    Milton, Anna
    Rivera, Juan
    Garris, Rebecca
    Ravandi, Farhad
    Kantarjian, Hagop M.
    BLOOD, 2023, 142
  • [35] Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis
    Jabbour, Elias J.
    Sasaki, Koji
    Ravandi, Farhad
    Short, Nicholas J.
    Garcia-Manero, Guillermo
    Daver, Naval
    Kadia, Tapan
    Konopleva, Marina
    Jain, Nitin
    Cortes, Jorge
    Issa, Ghayas C.
    Jacob, Jovitta
    Kwari, Monica
    Thompson, Philip
    Garris, Rebecca
    Pemmaraju, Naveen
    Yilmaz, Musa
    O'Brien, Susan M.
    Kantarjian, Hagop M.
    CANCER, 2019, 125 (15) : 2579 - 2586
  • [36] Inotuzumab ozogamicin (IO) in combination with low-intensity chemotherapy as front-line therapy for older patients (pts) and as salvage therapy for adult with R/R acute lymphoblastic leukemia (ALL).
    Jabbour, Elias
    O'Brien, Susan Mary
    Jain, Nitin
    Thomas, Deborah A.
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    Borthakur, Gautam
    York, Sergernne
    Garris, Rebecca
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [37] Updated results from a phase II study of mini-hyper-CVD (mini-HCVD) plus inotuzumab ozogamicin (INO), with or without blinatumomab (Blina), in older adults with newly diagnosed Philadelphia chromosome (Ph)-negative B-cell acute lymphoblastic leukemia (ALL).
    Macaron, Walid
    Kantarjian, Hagop M.
    Short, Nicholas James
    Ravandi, Farhad
    Jain, Nitin
    Kadia, Tapan M.
    Haddad, Fadi
    Valero, Yesid Alvarado
    Daver, Naval Guastad
    Borthakur, Gautam
    Dinardo, Courtney Denton
    Konopleva, Marina
    Wierda, William G.
    Jacob, Jovitta
    Roy, Edith
    Loiselle, Christopher
    Milton, Anna
    Rivera, Juan
    Garris, Rebecca
    Jabbour, Elias
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [38] Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study
    Kantarjian, Hagop
    Ravandi, Farhad
    Short, Nicholas J.
    Huang, Xuelin
    Jain, Nitin
    Sasaki, Koji
    Daver, Naval
    Pemmaraju, Naveen
    Khoury, Joseph D.
    Jorgensen, Jeffrey
    Alvarado, Yesid
    Konopleva, Marina
    Garcia-Manero, Guillermo
    Kadia, Tapan
    Yilmaz, Musa
    Bortakhur, Gautam
    Burger, Jan
    Kornblau, Steven
    Wierda, William
    DiNardo, Courtney
    Ferrajoli, Alessandra
    Jacob, Jovitta
    Garris, Rebecca
    O'Brien, Susan
    Jabbour, Elias
    LANCET ONCOLOGY, 2018, 19 (02): : 240 - 248
  • [39] A Phase II Study of Mini-Hyper-CVD Plus Venetoclax in Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
    Venugopal, Sangeetha
    Kantarjian, Hagop
    Short, Nicholas J.
    Thompson, Philip A.
    Pemmaraju, Naveen
    Jain, Nitin
    Wierda, William G.
    Borthakur, Gautam
    Montalban-Bravo, Guillermo
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Kadia, Tapan M.
    Ohanian, Maro
    Chien, Kelly S.
    Thankachan, Jennifer
    Nwakanme, Benjamin
    Garris, Rebecca
    Jabbour, Elias J.
    BLOOD, 2021, 138
  • [40] Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia A Phase 2 Clinical Trial
    Jabbour, Elias
    Ravandi, Farhad
    Kebriaei, Partow
    Huang, Xuelin
    Short, Nicholas J.
    Thomas, Deborah
    Sasaki, Koji
    Rytting, Michael
    Jain, Nitin
    Konopleva, Marina
    Garcia-Manero, Guillermo
    Champlin, Richard
    Marin, David
    Kadia, Tapan
    Cortes, Jorge
    Estrov, Zeev
    Takahashi, Koichi
    Patel, Yogin
    Khouri, Maria R.
    Jacob, Jovitta
    Garris, Rebecca
    O'Brien, Susan
    Kantarjian, Hagop
    JAMA ONCOLOGY, 2018, 4 (02) : 230 - 234
12345